Navigation Links
Codexis Names Veteran Chemical Executive to Lead Codexis do Brasil
Date:10/11/2011

REDWOOD CITY, Calif., Oct. 11, 2011 /PRNewswire/ -- Codexis, Inc. (Nasdaq: CDXS) today announced that Achilles Antonio Clement has been named Director, Latin America. He will head the newly-formed Codexis do Brasil Participacoes Ltda., with responsibility for managing Codexis' expanding role in Latin America. He will report to David Anton, Ph.D., Chief Technology Officer and SVP, Process Development and Manufacturing.

"Achilles Clement brings Codexis broad experience in building and leading fuels and chemicals businesses in Latin America," Dr. Anton said. "Brazil is the world's fastest growing market for biofuels. His appointment, and the establishment of Codexis do Brasil, are significant elements of our growth strategy in this important region. We are very pleased to welcome Achilles to our leadership team."

This announcement follows the signing last month of a joint development agreement between Codexis and Raizen Energia S.A, Brazil's largest sugar and ethanol producer, to develop an improved first generation ethanol process with enhanced performance economics.

Mr. Clement joins Codexis after more than 40 years in operations, sales and business development with DuPont in Latin America. He most recently served as Vice President, Global Business Development and earlier, Vice President of Sales, for DuPont's safety and environmental consulting division in Latin America.  He was also active in developing new biofuels, including ethanol and butanol in the region.

Previously, Mr. Clement led sales, marketing and production for DuPont's titanium dioxide business, serving the plastics, paint and paper industries, and held senior business development management positions in the company's chemicals business.  Prior to DuPont, he spent six years as a field manager in various sugar mills.  He holds a degree in agronomy from the School of Agronomy Luiz de Queiroz, Piracicaba, Brazil.

Codexis is an industrial biotechnology company developing products that make manufacturing processes faster, cleaner and cheaper. Codexis' technology is commercialized with leading global pharmaceutical companies and is in development for advanced biofuels with Shell and for biobased chemicals.  For more information, visit www.codexis.com.

Forward-Looking Statements

This press release contains forward-looking statements relating to Codexis' opportunities to improve the performance and cost structure of first generation ethanol with Raizen.  You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could materially affect actual results.  Important factors known to Codexis that could materially affect actual results include Codexis' dependence on the performance of other parties, including Raizen; Codexis' ability to grow its business if Codexis is unable to commercialize its technology in biofuels; fluctuations in the price of and demand for petroleum-based products may reduce demand for biofuels; the availability of renewable feedstocks may limit Codexis' biofuel opportunities; the demand for biofuels may be significantly reduced by reductions or changes to existing fuel regulations and policies; and risks associated with Codexis' international business.  Additional factors that could cause results to affect actual results can be found in Codexis' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 3, 2011, including under the caption "Risk Factors."  Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contacts:  
Media:  Lyn Christenson, lyn.christenson@codexis.com, 650.421.8144 or Saskia Sidenfaden, ssidenfaden@mww.com, 212.827.3771. Investors:  Henk Adriaenssens, ir@codexis.com, 650.421.8331


'/>"/>
SOURCE Codexis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Codexis Names Fernando Valle Research Fellow
2. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
3. Codexis Expands Collaboration with Teva
4. Codexis Expands Pharmaceutical Manufacturing Partnerships
5. Codexis, Inc. Announces Pricing of Initial Public Offering
6. Codexis CEO Alan Shaw Named Ernst & Young Entrepreneur Of The Year® 2010 Recipient in Northern California
7. Codexis Names Peter Strumph SVP, Commercial Operations
8. Codexis to Present at the Pacific Crest Technology Leadership Forum
9. Codexis Expands Codex® Panel Product Family at CPhI
10. Codexis to Announce Third Quarter 2010 Financial Results October 28, 2010
11. Codexis to Present at Piper Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 million ... continuing operations Second-quarter 2017 ... million Second-quarter 2017 Sterile ... Second-quarter 2017 adjusted diluted earnings ... to $0.93 Second-quarter 2017 ...
(Date:8/7/2017)... FLINT, Mich., Aug. 7, 2017  Diplomat Pharmacy, Inc. (NYSE: ... for the quarter ended June 30, 2017.  All comparisons, unless ... Second Quarter 2017 ... compared to $1,089 million, an increase of 3.5% ... Gross margin of 7.5% versus 7.6% ...
(Date:8/3/2017)... Aug. 3, 2017  Opioid addiction and other drugs ... healthcare costs and threatening outcomes, were problems taken on ... IVD industry that support them, met this week. This ... said that drugs of abuse, procalcitonin and acute kidney ... the organization,s 69th meeting in San Diego, ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... August 16, 2017 , ... ... their doors. They celebrate 30 years in business this year, and they’re marking ... inviting, tranquil space to serve their patients. , It stands to reason ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... ... Telehealth, Inc. has received a three-year grant totaling $975,000, renewing its funding from ... Health and Human Services. , This funding marks, the fourth time the HRSA ...
(Date:8/16/2017)... ... August 16, 2017 , ... SGNA ... endoscope after every reprocessing cycle, both between patient procedures and before storage, is ... Drying is as important to the prevention of disease transmission and nosocomial infection ...
(Date:8/16/2017)... Salt Lake City, Utah (PRWEB) , ... August 16, 2017 , ... ... its spot on the Inc 5000 list for the fourth consecutive year. ... the Inc. 5000 2017 list of the nation’s fastest growing companies. , ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... First ... United States, named Dr. Douglas J. Harrison, as the new Medical Director of its ... the new facility Medical Director of our Sienna Plantation location,” said Dr. Michael (Derek) ...
Breaking Medicine News(10 mins):